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This contribution reviews briefly the history ofthe discovery and characteriza-
tion ofpeptic activity; secretory models and current concepts regarding the reg-
ulation ofpepsinogen secretion; and evidence that pepsin is a necessary co-fac-
tor for gastroduodenal mucosal injury. Several animal studies indicate that pep-
tic activity is required for acid- and nonsteroidal anti-inflammatory drug-
induced gastroduodenal ulceration. A more vigorous approach to the develop-
ment ofanti-peptic drugs forthe treatment ofpepticulcerdisease isencouraged.
INTRODUCTION
The contribution ofpepsin to the pathogenesis ofgastroduodenal mucosal damage is
implicit in the term "peptic" ulcerdisease. Nonetheless, formany years continuing intothe
present era, elucidation of the physiology and pathophysiology of pepsinogen secretion
has taken a back seat to the study of gastric acid secretion. Likewise, medical therapy of
gastrointestinal mucosal damage has focused on agents that neutralize orinhibit the secre-
tion ofgastric acid. This, despite the importance ofgastric acid in preventing infection and
promoting the absorption of various nutrients. Surprisingly, little effort has been directed
to develop therapies that might inactivate pepsin or prevent the secretion of pepsinogen,
maneuvers that are less likely to disrupt gastric homeostasis and result in bacterial over-
growth, gastrin hypersecretion and other side-effects of acid suppression therapy.
In this paper, the author will review briefly the history of the discovery and charac-
terization of peptic activity; secretory models and current concepts regarding the regula-
tion of pepsinogen secretion; and evidence that pepsin is a necessary co-factor in the
development ofgastroduodenal mucosal damage.
THE DISCOVERY AND CHARACTERIZATION OF
PEPTIC ACTIVITY IN GASTRIC JUICE
The story of Dr. William Beaumont's experimentation on the Canadian fur trapper
Alexis St. Martin is known to anyone with an interest in gastric physiology. In a series of
experiments performed during the 1820s and 1830s, Beaumont took advantage of St.
Martin's gastro-cutaneous fistula to study aspects of gastric function. Among many sig-
nificant observations, these studies confirmed that the human stomach secretes hydrochlo-
ric acid. Nonetheless, it is not generally appreciated that Beaumont anticipated the dis-
covery ofpepsin. In a simple, but brilliant, experiment, Beaumont prepared a mixture of
dilute hydrochloric acid, water and saliva that was adjusted (by taste!) to mimic gastric
juice. Identical pieces of meat were suspended in equal volumes ofthis mixture and gas-
tricjuice that had been removed from St. Martin's stomach.
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Into 3 drachms of this mixture immersed XX grs. lean broiled beefsteak unmasticated, but
chopped fine with a knife, & for a comparison put the same qty. and kind of meat into 3
drachms gastric juice, and placed them on the bath and treated them together for 6 hours.
When the meat in the gastricjuice was taken out and filtered dry, weighed 2 grs. only; that in
the artificial menstrum was not dim-iinished in weight at all, but had lost its fibrous form and
became a jelly-like mass, thick and tremulous, like half dissolved glue-not converted into
anything like chyme, nor bore much resemblance to the contents of the gastricjuice [1].
From this experiment, Beaumont concludedthat, in addition to acid, gastricjuice con-
tained a constituent that promoted the digestion of meat. In 1836, acknowledging
Beaumont's contribution, Theodor Schwann coined the name pepsin for a proteolytic con-
stituent ofgastricjuice that was activated by acid and inactivated by alkali [2]. Subsequent
investigations from the laboratories ofWasmann, and particularly Langley during the late
1800s, resulted in the discovery that pepsin is secreted as a proenzyme, designated
pepsinogen [3-5]. Pepsin (mol. wt., 35.5 kDa) and pepsinogen (mol. wt., 42.5 kDa) were
crystallized by Northrop [6] and Herriott [7], respectively.
Herriot established that at acidic pH (< 6.0) pepsinogen undergoes autocatalysis
whereby a 3.1-kDa inhibitory piece is cleaved from the N-terminal portion of the mole-
cule and digested by the resulting pepsin as the pH drops below 4.0 [8]. The pH optimum
for pepsin, depending on the substrate, ranges between 1.0 and 3.0 [9, 10]. Commonly,
peptic activity is determined by examining the acid hydrolysis of native or radiolabeled
hemoglobin or albumin (measuring the release into the medium oftyrosine or radiolabel,
respectively).
PHYSIOLOGICAL MODELS USED TO STUDY PEPSINOGEN SECRETION
As in Beaumont's experiments, models examining secretion in intact, innervated
tomachs provide the most physiological approximation of pepsinogen secretion in
iumans and other species. Nevertheless, because gastricjuice is comprised ofcomponents
secreted by a variety of cells, dissecting the relative contribution of neural and hormonal
stimuli to the control of pepsinogen secretion may be quite difficult. "Wash-out" of pre-
formed pepsinogen from gastric glands along with fluid and electrolytes may result in
overestimation of secretion. Hence, investigators have developed peptic models, like
mucosal cell cultures, gastric glands and dispersed chief cells, which obviate some of
these difficulties. The major disadvantage ofthese models, including the use ofdispersed
peptic cells from human stomach [11], is that physiological cell-cell interactions may be
lost.
REGULATION OF PEPSINOGEN SECRETION
The following represents abriefdescription ofthe regulation ofpepsinogen secretion.
For amore detailed analysis ofsignal transduction pathways in gastric chiefcells the read-
er may consult a recent review [12].
In general, there are two majorsignal transduction pathways that mediate pepsinogen
secretion (Figure 1). In one pathway, the interaction of agents like cholecystokinin, gas-
trin and cholinergic agonists with specific cell membrane receptors results in the activa-
tion of phospholipase C, phospholipid turnover, and the production of inositol trisphos-
phate (Ip3)band diacylglycerol (DAG). In turn, IP3 stimulates the release ofcalcium from
intracellular stores thereby activating kinases, like calcium/calmodulin kinase-II [13], and
phosphatases, like protein phosphatase-2B (calcineurin) [14]. DAG directly activates dif-
ferent isoforms ofprotein kinase C [15].
In the other pathway, the interaction ofagents like vasoactive intestinal peptide, pitu-
itary adenylyl cyclase activating peptide, secretin, glucagon-like peptide-1, prostaglandins
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Figure 1. Cartoon illustrating cellular regulation ofpepsinogensecretion fromdispersed chief
cells fromguineapigstomach. Onleft, colors indicate three sets ofagents: thosethat activatephos-
pholipase C and phospholipid turnover, those that activate adenylyl cyclase and cause a rise in cel-
lular cAMP, and those that inhibit agonist-induced stimulation ofadenylyl cyclase. Increases in cel-
lularcalcium, cAMPand DAG activatekinases andphosphatases that mediatepepsinogen secretion.
Broken arrow indicates interaction between the phospholipase C and adenylyl cyclase pathways.
Question mark indicates distal components ofsignalling pathways that remain to beelucidated. Gq,
Gs, Gi = guanine nucleotide binding proteins; IP3 = inositol trisphosphate; DAG = diacylglycerol.
and cholera toxin with specific cell-membrane receptors results in the activation ofadeny-
lyl cyclase and the production of cAMP. cAMP directly activates protein kinase A.
Although some evidence exists that somatostatin, peptide YY and neuropeptide Y may
negatively modulate adenylyl cyclase in dispersed chief cells, the physiological impor-
tance ofthis observation is not clear [16-18].
Besides the initiation of cascades that result in activation of protein kinases and/or
phosphatases, similarities between these signal transduction pathways include the involve-
ment ofheterotrimeric guanine nucleotide binding proteins, like Gq and Gs, in mediating
the steps following ligand-receptor interaction. Moreover, there is evidence ofinteraction
between the phospholipase C and adenylyl cyclase pathways, so-called "cross-talk,"
which results in augmentation ofcellular levels ofcAMP and potentiation ofpepsinogen
secretion (indicated by the broken arrow in Figure 1) [19, 20].
The current focus ofactivity in ourlaboratory is identification and characterization of
the substrates for activated chiefcell kinases and phosphatases (note the question mark in
Figure 1). For example, recent work indicates that agonist-induced increases in chiefcell
calcium concentration results in activation of protein phosphatase-2B and a consequent
reduction in the phosphorylation of 18- and 55-kDa cytoskeletal proteins [14].
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Identification and characterization of this protein may be very helpful in elucidating the
distal steps that mediate pepsinogen secretion.
ROLE OF PEPSIN IN THE DEVELOPMENT OF
GASTRODUODENAL MUCOSAL DAMAGE
The precise mechanism(s) leading to gastroduodenal mucosal ulceration remains
enigmatic. Despite recent interest in the association ofHelicobacterpylori infection with
ulceration, it is not yet clear how the presence of this organism facilitates mucosal injury.
Nevertheless, it is apparent that factors such as an increase in the luminal concentration of
hydrochloric acid, gastric mucosal ischemia and drugs, such as non-steroidal anti-inflam-
matory drugs (NSAIDs), that break down the mucosal barrier predispose to ulceration.
Many of these events are associated with a drop in intramucosal pH, which leads to acti-
vation of pepsinogen to pepsin, and approaches the pH optimum for this acid protease.
Several observations indicate that pepsin is a necessary co-factor for gastric mucosal
ulceration. Early studies indicated that the addition ofpepsin to acid perfusates ofcanine
or feline stomach or intestine, respectively, increased the likelihood and severity of
mucosal ulceration [21-23]. More recent studies indicate not only that pepsin potentiates
acid injury to the gastrointestinal tract, but that, in the absence ofpepsin, acid may be rel-
atively innocuous. In rats, Alphin et al. [24] found that inhibition of peptic activity pre-
vented gastric ulceration even when the pH of the perfusate was as low as 1.3. Ford et al.
[25] demonstrated that acid proteinase activity in rat gastric mucosa increased following
ischemia and that this was associated with mucosal erosion. Treatment with luminal
inhibitors ofpeptic activity reduced tissue proteinase activity and the number of erosions
[25]. Similar findings were observed by Joffe et al. [26] when rat duodena were perfused
in the absence or presence ofpepsin.
In a recent study, Gaw et al. [27] treated rats with subcutaneous indomethacin after
they had received a pepsin inhibitor (pepstatin-A) or vehicle orally. Treatment with the
pepsin inhibitor caused a dose-dependent decrease in indomethacin-induced gastric antral
mucosal ulceration. Moreover, ulceration under these conditions was prevented even if
acidified methylcellulose ([HCl] = 100 mM) was given orally [27]. In contrast, treatment
with a histamine-2 receptor blocker decreased indomethacin-induced ulceration but did
not prevent the lesions caused by the addition of acid methylcellulose. Hence, these stud-
ies indicate that pepsin is an obligatory co-factor for acid- and indomethacin-induced
mucosal damage.
CONCLUSIONS
For nearly a century, peptic ulcer therapy focused on neutralization of gastric acid
with antacids, or the suppression of acid secretion with anticholinergics, vagotomy, H2-
blockers or, more recently, proton pump inhibitors. As reviewed above, it is conceivable
that the major benefit derived from anti-acid therapy is the maintenance of a luminal pH
> 4.0 that decreases conversion of pepsinogen to pepsin and creates an environment that
is suboptimal for the proteolytic actions ofthe acid protease. Despite the recent revolution
in therapy caused by recognition ofthe role ofH. pylori in ulcerdisease, current treatment
recommendations for acute ulceration regard antibiotics as adjuncts to measures that
reduce gastric acid. Moreover, several studies have found that H. pylori plays no role in
the pathogenesis of an increasingly important fraction of the ulcer population, those
caused by NSAID use. Hence, given the datapresented in this review, it appears that ulcer
therapy directed atinhibiting peptic activity may be the only approach that is likely to pre-
vent or heal ulcers caused by gastric acid, H. pylori infection or the use ofNSAIDs with-
out the potential side effects associated with antisecretory drugs, antibiotics and
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prostaglandins. More research directed at developing clinically useful anti-peptic therapy
is warranted.
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